GSK will split into two new companies in 2022, they are GSK and Haleon. So what does this spin-off mean for Malaysia and the healthcare industry? Philip See speaks to Dr. Jonathan Pan, Vice President and GM of Malaysia and Brunei at GSK about their top-selling drugs, their role in the Covid-19 pandemic, and can Malaysia be a vaccine manufacturing hub?

Can ASEAN’s Digital Needs Push EdgePoint Past Key Pressures?
23:32

Pharmaniaga Post-PN17 Betting Big on Biopharma
23:56

Khairy Jamaluddin: Back in the Running
34:25